A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer
Conclusion: At therapeutic dosage levels, pharmacokinetic behavior and safety profiles were similar for both formulations. Chinese National Registry Code: ChiCTR-IPR-15005856.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Constipation | Cytology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study